关于「 malignant」的内容列表

CureX announces the start of using business revenue to buy back and destroy CUX tokens

On January 23rd, CureX recently announced that 20% of the sales of its TRC-T products for the treatment of malignant synovial sarcoma will be used to buy back CUX and destroy it. This operation marks CureX's further strengthening of the value and market stability of CUX tokens while promoting the application of its biotech products. In the first round of repurchases, CureX purchased 100 SOL and destroyed 4259,993 CUX tokens. CureX promises to continue to use a portion of its product revenue to b...

clock
2025-01-23 18:16:50